However, the clinical use of VEGF-targeted therapies is hindered by the potential side effects such as hypertension, proteinuria, bleeding, and cardiovascular complications in achieving optimal therapeutic concentrations (44,45). This evidence concerns the gene VEGFA and Hypertension.